BACKGROUND: Although whole lung irradiation is used to treat pulmonary metastases of pediatric solid malignancies, few studies have addressed its long-term pulmonary consequences. METHODS: The authors conducted a retrospective study of longitudinal changes in 171 pulmonary function tests (PFTs) and their relation with clinical features in 48 survivors of pediatric malignant solid tumors treated with whole lung irradiation. RESULTS: Although active respiratory symptoms were seen in only 9 patients (18.8%), abnormalities in forced vital capacity (FVC; 58.3%), forced expiratory volume in 1 second (FEV(1) ; 64.6%), total lung capacity (TLC; 72.9%), and diffusion capacity of the lung for carbon monoxide corrected for hemoglobin (DLCO(corr) ; 70.8%) were common. At a median follow-up of 9.7 years after whole lung irradiation, FVC, FEV(1) , and TLC significantly declined longitudinally (P = .04, .03, and .02, respectively). Focal pulmonary boost irradiation was significantly associated with abnormal FEV(1) /FVC (P = .03), forced expiratory flow between 25% and 75% forced vital capacity (P = .005), residual volume (RV; P = .005), and RV/TLC (P = .002). Ten patients had baseline PFTs, and FVC, FEV(1) , TLC, and DLCO(corr) worsened immediately after radiation, followed by transient improvement but subsequent decline. Thirteen of 32 (40.6%) patients aged >18 years were smokers. CONCLUSIONS: Pulmonary dysfunction was prevalent after whole lung irradiation and worsened over time, although most patients were asymptomatic. Boost irradiation impaired pulmonary function, and a significant proportion of patients were smokers. Further studies are planned to assess the predictors and clinical consequences of progressive PFT abnormalities and to evaluate educational interventions.
BACKGROUND: Although whole lung irradiation is used to treat pulmonary metastases of pediatric solid malignancies, few studies have addressed its long-term pulmonary consequences. METHODS: The authors conducted a retrospective study of longitudinal changes in 171 pulmonary function tests (PFTs) and their relation with clinical features in 48 survivors of pediatric malignant solid tumors treated with whole lung irradiation. RESULTS: Although active respiratory symptoms were seen in only 9 patients (18.8%), abnormalities in forced vital capacity (FVC; 58.3%), forced expiratory volume in 1 second (FEV(1) ; 64.6%), total lung capacity (TLC; 72.9%), and diffusion capacity of the lung for carbon monoxide corrected for hemoglobin (DLCO(corr) ; 70.8%) were common. At a median follow-up of 9.7 years after whole lung irradiation, FVC, FEV(1) , and TLC significantly declined longitudinally (P = .04, .03, and .02, respectively). Focal pulmonary boost irradiation was significantly associated with abnormal FEV(1) /FVC (P = .03), forced expiratory flow between 25% and 75% forced vital capacity (P = .005), residual volume (RV; P = .005), and RV/TLC (P = .002). Ten patients had baseline PFTs, and FVC, FEV(1) , TLC, and DLCO(corr) worsened immediately after radiation, followed by transient improvement but subsequent decline. Thirteen of 32 (40.6%) patients aged >18 years were smokers. CONCLUSIONS:Pulmonary dysfunction was prevalent after whole lung irradiation and worsened over time, although most patients were asymptomatic. Boost irradiation impaired pulmonary function, and a significant proportion of patients were smokers. Further studies are planned to assess the predictors and clinical consequences of progressive PFT abnormalities and to evaluate educational interventions.
Authors: P Paoletti; G Viegi; G Pistelli; F Di Pede; P Fazzi; R Polato; M Saetta; R Zambon; G Carli; C Giuntini Journal: Am Rev Respir Dis Date: 1985-10
Authors: Amir Soltani; David W Reid; Sukhwinder S Sohal; Richard Wood-Baker; Steve Weston; H Konrad Muller; E Haydn Walters Journal: Respir Res Date: 2010-07-30
Authors: Ann C Mertens; Yutaka Yasui; Yan Liu; Marilyn Stovall; Ray Hutchinson; Jill Ginsberg; Charles Sklar; Leslie L Robison Journal: Cancer Date: 2002-12-01 Impact factor: 6.921
Authors: Uta Dirksen; Bernadette Brennan; Marie-Cécile Le Deley; Nathalie Cozic; Henk van den Berg; Vivek Bhadri; Bénédicte Brichard; Line Claude; Alan Craft; Susanne Amler; Natalie Gaspar; Hans Gelderblom; Robert Goldsby; Richard Gorlick; Holcombe E Grier; Jean-Marc Guinbretiere; Peter Hauser; Lars Hjorth; Katherine Janeway; Heribert Juergens; Ian Judson; Mark Krailo; Jarmila Kruseova; Thomas Kuehne; Ruth Ladenstein; Cyril Lervat; Stephen L Lessnick; Ian Lewis; Claude Linassier; Perrine Marec-Berard; Neyssa Marina; Bruce Morland; Hélène Pacquement; Michael Paulussen; R Lor Randall; Andreas Ranft; Gwénaël Le Teuff; Keith Wheatley; Jeremy Whelan; Richard Womer; Odile Oberlin; Douglas S Hawkins Journal: J Clin Oncol Date: 2019-09-25 Impact factor: 50.717